Searching map area
Safety and Efficacy Study of NabĀ®-Paclitaxel With CC-486 or NabĀ®-Paclitaxel With Durvalumab, and NabĀ®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
? TBD
clinical trial related to cancer immunotherapy, retrieved from clinicaltrials.gov
Join to rate
Ratings 0
Nobody has rated this yet. Be the first!
Lists 0
Join to rate
Instance of
Clinical trial
Subject
Cancer immunotherapy
References
Wikidata